nodes	percent_of_prediction	percent_of_DWPC	metapath
Naproxen—PTGS2—colon cancer	0.367	1	CbGaD
Naproxen—UGT1A1—Irinotecan—colon cancer	0.115	0.278	CbGbCtD
Naproxen—SLCO1A2—Methotrexate—colon cancer	0.0445	0.108	CbGbCtD
Naproxen—ALB—Irinotecan—colon cancer	0.0435	0.106	CbGbCtD
Naproxen—ALB—Fluorouracil—colon cancer	0.0417	0.101	CbGbCtD
Naproxen—CYP2C9—Capecitabine—colon cancer	0.0379	0.0921	CbGbCtD
Naproxen—CYP2C8—Fluorouracil—colon cancer	0.0322	0.0783	CbGbCtD
Naproxen—SLC22A6—Methotrexate—colon cancer	0.027	0.0656	CbGbCtD
Naproxen—CYP1A2—Fluorouracil—colon cancer	0.025	0.0606	CbGbCtD
Naproxen—ALB—Methotrexate—colon cancer	0.023	0.0558	CbGbCtD
Naproxen—CYP2C9—Fluorouracil—colon cancer	0.0225	0.0546	CbGbCtD
Naproxen—AKR1C3—Vinblastine—Vincristine—colon cancer	0.00334	1	CbGdCrCtD
Naproxen—ALB—gall bladder—colon cancer	0.00177	0.0558	CbGeAlD
Naproxen—UGT2B7—renal system—colon cancer	0.00148	0.0468	CbGeAlD
Naproxen—AKR1C3—smooth muscle tissue—colon cancer	0.00142	0.0448	CbGeAlD
Naproxen—UGT1A1—renal system—colon cancer	0.00126	0.0398	CbGeAlD
Naproxen—UGT2B7—digestive system—colon cancer	0.00121	0.0384	CbGeAlD
Naproxen—PTGS1—endothelium—colon cancer	0.00116	0.0367	CbGeAlD
Naproxen—PTGS2—endothelium—colon cancer	0.00111	0.0351	CbGeAlD
Naproxen—PTGS1—blood vessel—colon cancer	0.00107	0.0338	CbGeAlD
Naproxen—UGT1A1—digestive system—colon cancer	0.00103	0.0326	CbGeAlD
Naproxen—AKR1C3—bone marrow—colon cancer	0.00103	0.0326	CbGeAlD
Naproxen—PTGS2—blood vessel—colon cancer	0.00102	0.0323	CbGeAlD
Naproxen—AKR1C3—vagina—colon cancer	0.000988	0.0313	CbGeAlD
Naproxen—PTGS2—gall bladder—colon cancer	0.000962	0.0304	CbGeAlD
Naproxen—UGT2B7—liver—colon cancer	0.000904	0.0286	CbGeAlD
Naproxen—SLCO1A2—renal system—colon cancer	0.000852	0.027	CbGeAlD
Naproxen—AKR1C3—liver—colon cancer	0.000834	0.0264	CbGeAlD
Naproxen—Nabumetone—PTGS2—colon cancer	0.00081	0.154	CrCbGaD
Naproxen—Carprofen—PTGS2—colon cancer	0.000772	0.147	CrCbGaD
Naproxen—UGT1A1—liver—colon cancer	0.000769	0.0243	CbGeAlD
Naproxen—Indomethacin—PPARG—colon cancer	0.000719	0.136	CrCbGaD
Naproxen—SLCO1A2—digestive system—colon cancer	0.000699	0.0221	CbGeAlD
Naproxen—AKR1C3—lymph node—colon cancer	0.000639	0.0202	CbGeAlD
Naproxen—PTGS2—embryo—colon cancer	0.00061	0.0193	CbGeAlD
Naproxen—CYP2C8—renal system—colon cancer	0.000595	0.0188	CbGeAlD
Naproxen—Ibuprofen—PPARG—colon cancer	0.000566	0.107	CrCbGaD
Naproxen—CYP1A2—renal system—colon cancer	0.000557	0.0176	CbGeAlD
Naproxen—SLCO1A2—liver—colon cancer	0.000521	0.0165	CbGeAlD
Naproxen—PTGS1—epithelium—colon cancer	0.00052	0.0165	CbGeAlD
Naproxen—ALB—liver—colon cancer	0.000518	0.0164	CbGeAlD
Naproxen—PTGS1—smooth muscle tissue—colon cancer	0.000501	0.0159	CbGeAlD
Naproxen—PTGS2—epithelium—colon cancer	0.000497	0.0157	CbGeAlD
Naproxen—PTGS1—renal system—colon cancer	0.000483	0.0153	CbGeAlD
Naproxen—PTGS2—smooth muscle tissue—colon cancer	0.000479	0.0152	CbGeAlD
Naproxen—Suprofen—PTGS2—colon cancer	0.000477	0.0905	CrCbGaD
Naproxen—PTGS2—renal system—colon cancer	0.000461	0.0146	CbGeAlD
Naproxen—CYP1A2—digestive system—colon cancer	0.000457	0.0145	CbGeAlD
Naproxen—CYP2C9—digestive system—colon cancer	0.000434	0.0137	CbGeAlD
Naproxen—CYP2C8—vagina—colon cancer	0.000431	0.0136	CbGeAlD
Naproxen—Fenoprofen—PTGS2—colon cancer	0.000411	0.078	CrCbGaD
Naproxen—ALB—lymph node—colon cancer	0.000397	0.0126	CbGeAlD
Naproxen—PTGS1—digestive system—colon cancer	0.000396	0.0125	CbGeAlD
Naproxen—PTGS2—lymphoid tissue—colon cancer	0.000383	0.0121	CbGeAlD
Naproxen—PTGS2—digestive system—colon cancer	0.000378	0.012	CbGeAlD
Naproxen—CYP2C8—liver—colon cancer	0.000364	0.0115	CbGeAlD
Naproxen—PTGS1—vagina—colon cancer	0.00035	0.0111	CbGeAlD
Naproxen—PTGS2—bone marrow—colon cancer	0.000349	0.011	CbGeAlD
Naproxen—CYP1A2—liver—colon cancer	0.00034	0.0108	CbGeAlD
Naproxen—PTGS2—vagina—colon cancer	0.000334	0.0106	CbGeAlD
Naproxen—CYP2C9—liver—colon cancer	0.000323	0.0102	CbGeAlD
Naproxen—Indomethacin—PTGS2—colon cancer	0.000303	0.0576	CrCbGaD
Naproxen—PTGS2—liver—colon cancer	0.000282	0.00892	CbGeAlD
Naproxen—Flurbiprofen—PTGS2—colon cancer	0.000268	0.0509	CrCbGaD
Naproxen—Indomethacin—ABCB1—colon cancer	0.000258	0.049	CrCbGaD
Naproxen—Ketoprofen—PTGS2—colon cancer	0.000243	0.0461	CrCbGaD
Naproxen—Ibuprofen—PTGS2—colon cancer	0.000239	0.0453	CrCbGaD
Naproxen—PTGS1—lymph node—colon cancer	0.000226	0.00715	CbGeAlD
Naproxen—PTGS2—lymph node—colon cancer	0.000216	0.00684	CbGeAlD
Naproxen—Ibuprofen—ABCB1—colon cancer	0.000203	0.0386	CrCbGaD
Naproxen—Nervous system disorder—Irinotecan—colon cancer	0.000193	0.00115	CcSEcCtD
Naproxen—Agranulocytosis—Capecitabine—colon cancer	0.000193	0.00115	CcSEcCtD
Naproxen—Thrombocytopenia—Irinotecan—colon cancer	0.000193	0.00115	CcSEcCtD
Naproxen—Anorexia—Vincristine—colon cancer	0.000193	0.00115	CcSEcCtD
Naproxen—Hyperhidrosis—Irinotecan—colon cancer	0.000191	0.00113	CcSEcCtD
Naproxen—Confusional state—Fluorouracil—colon cancer	0.00019	0.00113	CcSEcCtD
Naproxen—Mood swings—Methotrexate—colon cancer	0.000189	0.00112	CcSEcCtD
Naproxen—Hypotension—Vincristine—colon cancer	0.000189	0.00112	CcSEcCtD
Naproxen—Anaphylactic shock—Fluorouracil—colon cancer	0.000189	0.00112	CcSEcCtD
Naproxen—Oedema—Fluorouracil—colon cancer	0.000189	0.00112	CcSEcCtD
Naproxen—Anorexia—Irinotecan—colon cancer	0.000188	0.00112	CcSEcCtD
Naproxen—Infection—Fluorouracil—colon cancer	0.000188	0.00111	CcSEcCtD
Naproxen—Haemoglobin—Capecitabine—colon cancer	0.000187	0.00111	CcSEcCtD
Naproxen—Rhinitis—Capecitabine—colon cancer	0.000186	0.00111	CcSEcCtD
Naproxen—Haemorrhage—Capecitabine—colon cancer	0.000186	0.0011	CcSEcCtD
Naproxen—Hepatitis—Capecitabine—colon cancer	0.000186	0.0011	CcSEcCtD
Naproxen—Nervous system disorder—Fluorouracil—colon cancer	0.000185	0.0011	CcSEcCtD
Naproxen—Thrombocytopenia—Fluorouracil—colon cancer	0.000185	0.0011	CcSEcCtD
Naproxen—Liver function test abnormal—Methotrexate—colon cancer	0.000184	0.0011	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Vincristine—colon cancer	0.000184	0.0011	CcSEcCtD
Naproxen—Pharyngitis—Capecitabine—colon cancer	0.000184	0.00109	CcSEcCtD
Naproxen—Tachycardia—Fluorouracil—colon cancer	0.000184	0.00109	CcSEcCtD
Naproxen—Hypotension—Irinotecan—colon cancer	0.000184	0.00109	CcSEcCtD
Naproxen—Urinary tract disorder—Capecitabine—colon cancer	0.000183	0.00109	CcSEcCtD
Naproxen—Insomnia—Vincristine—colon cancer	0.000183	0.00109	CcSEcCtD
Naproxen—Oedema peripheral—Capecitabine—colon cancer	0.000183	0.00109	CcSEcCtD
Naproxen—Connective tissue disorder—Capecitabine—colon cancer	0.000182	0.00108	CcSEcCtD
Naproxen—Urethral disorder—Capecitabine—colon cancer	0.000182	0.00108	CcSEcCtD
Naproxen—Paraesthesia—Vincristine—colon cancer	0.000182	0.00108	CcSEcCtD
Naproxen—Breast disorder—Methotrexate—colon cancer	0.000181	0.00107	CcSEcCtD
Naproxen—Anorexia—Fluorouracil—colon cancer	0.00018	0.00107	CcSEcCtD
Naproxen—Toxic epidermal necrolysis—Methotrexate—colon cancer	0.00018	0.00107	CcSEcCtD
Naproxen—Visual impairment—Capecitabine—colon cancer	0.000179	0.00106	CcSEcCtD
Naproxen—Insomnia—Irinotecan—colon cancer	0.000178	0.00106	CcSEcCtD
Naproxen—Paraesthesia—Irinotecan—colon cancer	0.000177	0.00105	CcSEcCtD
Naproxen—Hypotension—Fluorouracil—colon cancer	0.000176	0.00105	CcSEcCtD
Naproxen—Decreased appetite—Vincristine—colon cancer	0.000176	0.00104	CcSEcCtD
Naproxen—Dyspnoea—Irinotecan—colon cancer	0.000176	0.00104	CcSEcCtD
Naproxen—Erythema multiforme—Capecitabine—colon cancer	0.000176	0.00104	CcSEcCtD
Naproxen—Somnolence—Irinotecan—colon cancer	0.000175	0.00104	CcSEcCtD
Naproxen—Gastrointestinal disorder—Vincristine—colon cancer	0.000175	0.00104	CcSEcCtD
Naproxen—Fatigue—Vincristine—colon cancer	0.000175	0.00104	CcSEcCtD
Naproxen—Eye disorder—Capecitabine—colon cancer	0.000174	0.00103	CcSEcCtD
Naproxen—Dyspepsia—Irinotecan—colon cancer	0.000174	0.00103	CcSEcCtD
Naproxen—Tinnitus—Capecitabine—colon cancer	0.000173	0.00103	CcSEcCtD
Naproxen—Constipation—Vincristine—colon cancer	0.000173	0.00103	CcSEcCtD
Naproxen—Pain—Vincristine—colon cancer	0.000173	0.00103	CcSEcCtD
Naproxen—Asthma—Methotrexate—colon cancer	0.000173	0.00103	CcSEcCtD
Naproxen—Cardiac disorder—Capecitabine—colon cancer	0.000172	0.00102	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000172	0.00102	CcSEcCtD
Naproxen—Decreased appetite—Irinotecan—colon cancer	0.000171	0.00102	CcSEcCtD
Naproxen—Eosinophilia—Methotrexate—colon cancer	0.000171	0.00102	CcSEcCtD
Naproxen—Insomnia—Fluorouracil—colon cancer	0.000171	0.00101	CcSEcCtD
Naproxen—Gastrointestinal disorder—Irinotecan—colon cancer	0.00017	0.00101	CcSEcCtD
Naproxen—Fatigue—Irinotecan—colon cancer	0.00017	0.00101	CcSEcCtD
Naproxen—Paraesthesia—Fluorouracil—colon cancer	0.00017	0.00101	CcSEcCtD
Naproxen—Pancreatitis—Methotrexate—colon cancer	0.000169	0.00101	CcSEcCtD
Naproxen—Pain—Irinotecan—colon cancer	0.000169	0.001	CcSEcCtD
Naproxen—Constipation—Irinotecan—colon cancer	0.000169	0.001	CcSEcCtD
Naproxen—Angiopathy—Capecitabine—colon cancer	0.000168	0.001	CcSEcCtD
Naproxen—Dyspnoea—Fluorouracil—colon cancer	0.000168	0.001	CcSEcCtD
Naproxen—Somnolence—Fluorouracil—colon cancer	0.000168	0.000997	CcSEcCtD
Naproxen—Immune system disorder—Capecitabine—colon cancer	0.000168	0.000996	CcSEcCtD
Naproxen—Mediastinal disorder—Capecitabine—colon cancer	0.000167	0.000994	CcSEcCtD
Naproxen—Chills—Capecitabine—colon cancer	0.000167	0.000989	CcSEcCtD
Naproxen—Dyspepsia—Fluorouracil—colon cancer	0.000166	0.000987	CcSEcCtD
Naproxen—Arrhythmia—Capecitabine—colon cancer	0.000166	0.000985	CcSEcCtD
Naproxen—Abdominal discomfort—Methotrexate—colon cancer	0.000166	0.000983	CcSEcCtD
Naproxen—Gastrointestinal pain—Vincristine—colon cancer	0.000166	0.000983	CcSEcCtD
Naproxen—Decreased appetite—Fluorouracil—colon cancer	0.000164	0.000975	CcSEcCtD
Naproxen—Alopecia—Capecitabine—colon cancer	0.000164	0.000974	CcSEcCtD
Naproxen—Pancytopenia—Methotrexate—colon cancer	0.000164	0.000974	CcSEcCtD
Naproxen—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000163	0.000968	CcSEcCtD
Naproxen—Mental disorder—Capecitabine—colon cancer	0.000163	0.000966	CcSEcCtD
Naproxen—Feeling abnormal—Irinotecan—colon cancer	0.000162	0.000965	CcSEcCtD
Naproxen—Malnutrition—Capecitabine—colon cancer	0.000162	0.00096	CcSEcCtD
Naproxen—Erythema—Capecitabine—colon cancer	0.000162	0.00096	CcSEcCtD
Naproxen—Dysuria—Methotrexate—colon cancer	0.000161	0.000959	CcSEcCtD
Naproxen—Pain—Fluorouracil—colon cancer	0.000161	0.000959	CcSEcCtD
Naproxen—Gastrointestinal pain—Irinotecan—colon cancer	0.000161	0.000957	CcSEcCtD
Naproxen—Abdominal pain—Vincristine—colon cancer	0.00016	0.00095	CcSEcCtD
Naproxen—Body temperature increased—Vincristine—colon cancer	0.00016	0.00095	CcSEcCtD
Naproxen—Flatulence—Capecitabine—colon cancer	0.000159	0.000946	CcSEcCtD
Naproxen—Photosensitivity reaction—Methotrexate—colon cancer	0.000158	0.000936	CcSEcCtD
Naproxen—Body temperature increased—Irinotecan—colon cancer	0.000156	0.000925	CcSEcCtD
Naproxen—Abdominal pain—Irinotecan—colon cancer	0.000156	0.000925	CcSEcCtD
Naproxen—Feeling abnormal—Fluorouracil—colon cancer	0.000156	0.000924	CcSEcCtD
Naproxen—Muscle spasms—Capecitabine—colon cancer	0.000155	0.000923	CcSEcCtD
Naproxen—Pneumonia—Methotrexate—colon cancer	0.000155	0.00092	CcSEcCtD
Naproxen—Drowsiness—Methotrexate—colon cancer	0.000154	0.000914	CcSEcCtD
Naproxen—Depression—Methotrexate—colon cancer	0.000154	0.000912	CcSEcCtD
Naproxen—Stevens-Johnson syndrome—Methotrexate—colon cancer	0.000153	0.000907	CcSEcCtD
Naproxen—Vision blurred—Capecitabine—colon cancer	0.000152	0.000905	CcSEcCtD
Naproxen—Tremor—Capecitabine—colon cancer	0.000151	0.000899	CcSEcCtD
Naproxen—Renal failure—Methotrexate—colon cancer	0.000151	0.000899	CcSEcCtD
Naproxen—Stomatitis—Methotrexate—colon cancer	0.00015	0.000891	CcSEcCtD
Naproxen—Ill-defined disorder—Capecitabine—colon cancer	0.00015	0.000891	CcSEcCtD
Naproxen—Urticaria—Fluorouracil—colon cancer	0.00015	0.000891	CcSEcCtD
Naproxen—Conjunctivitis—Methotrexate—colon cancer	0.00015	0.000889	CcSEcCtD
Naproxen—Anaemia—Capecitabine—colon cancer	0.000149	0.000887	CcSEcCtD
Naproxen—Body temperature increased—Fluorouracil—colon cancer	0.000149	0.000886	CcSEcCtD
Naproxen—Hypersensitivity—Vincristine—colon cancer	0.000149	0.000886	CcSEcCtD
Naproxen—Sweating—Methotrexate—colon cancer	0.000148	0.000877	CcSEcCtD
Naproxen—Haematuria—Methotrexate—colon cancer	0.000147	0.000872	CcSEcCtD
Naproxen—Malaise—Capecitabine—colon cancer	0.000146	0.000866	CcSEcCtD
Naproxen—Hepatobiliary disease—Methotrexate—colon cancer	0.000146	0.000865	CcSEcCtD
Naproxen—Epistaxis—Methotrexate—colon cancer	0.000145	0.000863	CcSEcCtD
Naproxen—Vertigo—Capecitabine—colon cancer	0.000145	0.000862	CcSEcCtD
Naproxen—Hypersensitivity—Irinotecan—colon cancer	0.000145	0.000862	CcSEcCtD
Naproxen—Asthenia—Vincristine—colon cancer	0.000145	0.000862	CcSEcCtD
Naproxen—Syncope—Capecitabine—colon cancer	0.000145	0.000861	CcSEcCtD
Naproxen—Leukopenia—Capecitabine—colon cancer	0.000145	0.000859	CcSEcCtD
Naproxen—Agranulocytosis—Methotrexate—colon cancer	0.000144	0.000853	CcSEcCtD
Naproxen—Palpitations—Capecitabine—colon cancer	0.000143	0.000848	CcSEcCtD
Naproxen—Loss of consciousness—Capecitabine—colon cancer	0.000142	0.000844	CcSEcCtD
Naproxen—Asthenia—Irinotecan—colon cancer	0.000141	0.00084	CcSEcCtD
Naproxen—Cough—Capecitabine—colon cancer	0.000141	0.000838	CcSEcCtD
Naproxen—Hypertension—Capecitabine—colon cancer	0.00014	0.000829	CcSEcCtD
Naproxen—Hypersensitivity—Fluorouracil—colon cancer	0.000139	0.000826	CcSEcCtD
Naproxen—Haemoglobin—Methotrexate—colon cancer	0.000139	0.000825	CcSEcCtD
Naproxen—Diarrhoea—Vincristine—colon cancer	0.000138	0.000822	CcSEcCtD
Naproxen—Haemorrhage—Methotrexate—colon cancer	0.000138	0.000821	CcSEcCtD
Naproxen—Hepatitis—Methotrexate—colon cancer	0.000138	0.000821	CcSEcCtD
Naproxen—Chest pain—Capecitabine—colon cancer	0.000138	0.000817	CcSEcCtD
Naproxen—Arthralgia—Capecitabine—colon cancer	0.000138	0.000817	CcSEcCtD
Naproxen—Myalgia—Capecitabine—colon cancer	0.000138	0.000817	CcSEcCtD
Naproxen—Pharyngitis—Methotrexate—colon cancer	0.000137	0.000815	CcSEcCtD
Naproxen—Anxiety—Capecitabine—colon cancer	0.000137	0.000814	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000137	0.000812	CcSEcCtD
Naproxen—Urinary tract disorder—Methotrexate—colon cancer	0.000137	0.000811	CcSEcCtD
Naproxen—Discomfort—Capecitabine—colon cancer	0.000136	0.000808	CcSEcCtD
Naproxen—Urethral disorder—Methotrexate—colon cancer	0.000136	0.000805	CcSEcCtD
Naproxen—Diarrhoea—Irinotecan—colon cancer	0.000135	0.000801	CcSEcCtD
Naproxen—Dry mouth—Capecitabine—colon cancer	0.000135	0.000799	CcSEcCtD
Naproxen—Dizziness—Vincristine—colon cancer	0.000134	0.000795	CcSEcCtD
Naproxen—Pruritus—Fluorouracil—colon cancer	0.000134	0.000793	CcSEcCtD
Naproxen—Visual impairment—Methotrexate—colon cancer	0.000133	0.000791	CcSEcCtD
Naproxen—Confusional state—Capecitabine—colon cancer	0.000133	0.00079	CcSEcCtD
Naproxen—Oedema—Capecitabine—colon cancer	0.000132	0.000783	CcSEcCtD
Naproxen—Infection—Capecitabine—colon cancer	0.000131	0.000778	CcSEcCtD
Naproxen—Erythema multiforme—Methotrexate—colon cancer	0.000131	0.000776	CcSEcCtD
Naproxen—Dizziness—Irinotecan—colon cancer	0.00013	0.000774	CcSEcCtD
Naproxen—Shock—Capecitabine—colon cancer	0.00013	0.000771	CcSEcCtD
Naproxen—Nervous system disorder—Capecitabine—colon cancer	0.000129	0.000768	CcSEcCtD
Naproxen—Eye disorder—Methotrexate—colon cancer	0.000129	0.000767	CcSEcCtD
Naproxen—Diarrhoea—Fluorouracil—colon cancer	0.000129	0.000767	CcSEcCtD
Naproxen—Thrombocytopenia—Capecitabine—colon cancer	0.000129	0.000767	CcSEcCtD
Naproxen—Tinnitus—Methotrexate—colon cancer	0.000129	0.000765	CcSEcCtD
Naproxen—Tachycardia—Capecitabine—colon cancer	0.000129	0.000765	CcSEcCtD
Naproxen—Vomiting—Vincristine—colon cancer	0.000129	0.000764	CcSEcCtD
Naproxen—Cardiac disorder—Methotrexate—colon cancer	0.000128	0.000762	CcSEcCtD
Naproxen—Skin disorder—Capecitabine—colon cancer	0.000128	0.000761	CcSEcCtD
Naproxen—Rash—Vincristine—colon cancer	0.000128	0.000758	CcSEcCtD
Naproxen—Hyperhidrosis—Capecitabine—colon cancer	0.000128	0.000757	CcSEcCtD
Naproxen—Dermatitis—Vincristine—colon cancer	0.000128	0.000757	CcSEcCtD
Naproxen—Headache—Vincristine—colon cancer	0.000127	0.000753	CcSEcCtD
Naproxen—Anorexia—Capecitabine—colon cancer	0.000126	0.000747	CcSEcCtD
Naproxen—Angiopathy—Methotrexate—colon cancer	0.000125	0.000745	CcSEcCtD
Naproxen—Vomiting—Irinotecan—colon cancer	0.000125	0.000744	CcSEcCtD
Naproxen—Immune system disorder—Methotrexate—colon cancer	0.000125	0.000742	CcSEcCtD
Naproxen—Dizziness—Fluorouracil—colon cancer	0.000125	0.000741	CcSEcCtD
Naproxen—Mediastinal disorder—Methotrexate—colon cancer	0.000125	0.00074	CcSEcCtD
Naproxen—Rash—Irinotecan—colon cancer	0.000124	0.000738	CcSEcCtD
Naproxen—Dermatitis—Irinotecan—colon cancer	0.000124	0.000737	CcSEcCtD
Naproxen—Chills—Methotrexate—colon cancer	0.000124	0.000737	CcSEcCtD
Naproxen—Headache—Irinotecan—colon cancer	0.000123	0.000733	CcSEcCtD
Naproxen—Hypotension—Capecitabine—colon cancer	0.000123	0.000732	CcSEcCtD
Naproxen—Alopecia—Methotrexate—colon cancer	0.000122	0.000725	CcSEcCtD
Naproxen—Mental disorder—Methotrexate—colon cancer	0.000121	0.000719	CcSEcCtD
Naproxen—Malnutrition—Methotrexate—colon cancer	0.00012	0.000715	CcSEcCtD
Naproxen—Erythema—Methotrexate—colon cancer	0.00012	0.000715	CcSEcCtD
Naproxen—Nausea—Vincristine—colon cancer	0.00012	0.000714	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Capecitabine—colon cancer	0.00012	0.000714	CcSEcCtD
Naproxen—Vomiting—Fluorouracil—colon cancer	0.00012	0.000713	CcSEcCtD
Naproxen—Insomnia—Capecitabine—colon cancer	0.000119	0.000709	CcSEcCtD
Naproxen—Rash—Fluorouracil—colon cancer	0.000119	0.000707	CcSEcCtD
Naproxen—Dermatitis—Fluorouracil—colon cancer	0.000119	0.000706	CcSEcCtD
Naproxen—Paraesthesia—Capecitabine—colon cancer	0.000118	0.000704	CcSEcCtD
Naproxen—Headache—Fluorouracil—colon cancer	0.000118	0.000702	CcSEcCtD
Naproxen—Dyspnoea—Capecitabine—colon cancer	0.000118	0.000699	CcSEcCtD
Naproxen—Nausea—Irinotecan—colon cancer	0.000117	0.000695	CcSEcCtD
Naproxen—Dyspepsia—Capecitabine—colon cancer	0.000116	0.00069	CcSEcCtD
Naproxen—Decreased appetite—Capecitabine—colon cancer	0.000115	0.000681	CcSEcCtD
Naproxen—Gastrointestinal disorder—Capecitabine—colon cancer	0.000114	0.000676	CcSEcCtD
Naproxen—Fatigue—Capecitabine—colon cancer	0.000114	0.000675	CcSEcCtD
Naproxen—Vision blurred—Methotrexate—colon cancer	0.000113	0.000674	CcSEcCtD
Naproxen—Constipation—Capecitabine—colon cancer	0.000113	0.00067	CcSEcCtD
Naproxen—Pain—Capecitabine—colon cancer	0.000113	0.00067	CcSEcCtD
Naproxen—Nausea—Fluorouracil—colon cancer	0.000112	0.000666	CcSEcCtD
Naproxen—Ill-defined disorder—Methotrexate—colon cancer	0.000112	0.000663	CcSEcCtD
Naproxen—Anaemia—Methotrexate—colon cancer	0.000111	0.000661	CcSEcCtD
Naproxen—Feeling abnormal—Capecitabine—colon cancer	0.000109	0.000646	CcSEcCtD
Naproxen—Malaise—Methotrexate—colon cancer	0.000109	0.000644	CcSEcCtD
Naproxen—Vertigo—Methotrexate—colon cancer	0.000108	0.000642	CcSEcCtD
Naproxen—Gastrointestinal pain—Capecitabine—colon cancer	0.000108	0.000641	CcSEcCtD
Naproxen—Leukopenia—Methotrexate—colon cancer	0.000108	0.00064	CcSEcCtD
Naproxen—Cough—Methotrexate—colon cancer	0.000105	0.000624	CcSEcCtD
Naproxen—Urticaria—Capecitabine—colon cancer	0.000105	0.000622	CcSEcCtD
Naproxen—Abdominal pain—Capecitabine—colon cancer	0.000104	0.000619	CcSEcCtD
Naproxen—Body temperature increased—Capecitabine—colon cancer	0.000104	0.000619	CcSEcCtD
Naproxen—Convulsion—Methotrexate—colon cancer	0.000104	0.000619	CcSEcCtD
Naproxen—Myalgia—Methotrexate—colon cancer	0.000102	0.000608	CcSEcCtD
Naproxen—Arthralgia—Methotrexate—colon cancer	0.000102	0.000608	CcSEcCtD
Naproxen—Chest pain—Methotrexate—colon cancer	0.000102	0.000608	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000102	0.000604	CcSEcCtD
Naproxen—Discomfort—Methotrexate—colon cancer	0.000101	0.000601	CcSEcCtD
Naproxen—Confusional state—Methotrexate—colon cancer	9.9e-05	0.000588	CcSEcCtD
Naproxen—Anaphylactic shock—Methotrexate—colon cancer	9.82e-05	0.000583	CcSEcCtD
Naproxen—Infection—Methotrexate—colon cancer	9.76e-05	0.000579	CcSEcCtD
Naproxen—Hypersensitivity—Capecitabine—colon cancer	9.72e-05	0.000577	CcSEcCtD
Naproxen—Nervous system disorder—Methotrexate—colon cancer	9.63e-05	0.000572	CcSEcCtD
Naproxen—Thrombocytopenia—Methotrexate—colon cancer	9.62e-05	0.000571	CcSEcCtD
Naproxen—Skin disorder—Methotrexate—colon cancer	9.54e-05	0.000567	CcSEcCtD
Naproxen—Hyperhidrosis—Methotrexate—colon cancer	9.49e-05	0.000564	CcSEcCtD
Naproxen—Asthenia—Capecitabine—colon cancer	9.47e-05	0.000562	CcSEcCtD
Naproxen—Anorexia—Methotrexate—colon cancer	9.36e-05	0.000556	CcSEcCtD
Naproxen—Pruritus—Capecitabine—colon cancer	9.33e-05	0.000554	CcSEcCtD
Naproxen—Hypotension—Methotrexate—colon cancer	9.18e-05	0.000545	CcSEcCtD
Naproxen—Diarrhoea—Capecitabine—colon cancer	9.03e-05	0.000536	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Methotrexate—colon cancer	8.95e-05	0.000531	CcSEcCtD
Naproxen—Insomnia—Methotrexate—colon cancer	8.88e-05	0.000528	CcSEcCtD
Naproxen—Paraesthesia—Methotrexate—colon cancer	8.82e-05	0.000524	CcSEcCtD
Naproxen—Dyspnoea—Methotrexate—colon cancer	8.76e-05	0.00052	CcSEcCtD
Naproxen—Somnolence—Methotrexate—colon cancer	8.73e-05	0.000519	CcSEcCtD
Naproxen—Dizziness—Capecitabine—colon cancer	8.72e-05	0.000518	CcSEcCtD
Naproxen—Dyspepsia—Methotrexate—colon cancer	8.65e-05	0.000513	CcSEcCtD
Naproxen—Decreased appetite—Methotrexate—colon cancer	8.54e-05	0.000507	CcSEcCtD
Naproxen—Gastrointestinal disorder—Methotrexate—colon cancer	8.48e-05	0.000504	CcSEcCtD
Naproxen—Fatigue—Methotrexate—colon cancer	8.47e-05	0.000503	CcSEcCtD
Naproxen—Pain—Methotrexate—colon cancer	8.4e-05	0.000499	CcSEcCtD
Naproxen—Vomiting—Capecitabine—colon cancer	8.39e-05	0.000498	CcSEcCtD
Naproxen—Rash—Capecitabine—colon cancer	8.32e-05	0.000494	CcSEcCtD
Naproxen—Dermatitis—Capecitabine—colon cancer	8.31e-05	0.000494	CcSEcCtD
Naproxen—Headache—Capecitabine—colon cancer	8.26e-05	0.000491	CcSEcCtD
Naproxen—Feeling abnormal—Methotrexate—colon cancer	8.09e-05	0.000481	CcSEcCtD
Naproxen—Gastrointestinal pain—Methotrexate—colon cancer	8.03e-05	0.000477	CcSEcCtD
Naproxen—Nausea—Capecitabine—colon cancer	7.84e-05	0.000465	CcSEcCtD
Naproxen—Urticaria—Methotrexate—colon cancer	7.8e-05	0.000463	CcSEcCtD
Naproxen—Abdominal pain—Methotrexate—colon cancer	7.76e-05	0.000461	CcSEcCtD
Naproxen—Body temperature increased—Methotrexate—colon cancer	7.76e-05	0.000461	CcSEcCtD
Naproxen—Hypersensitivity—Methotrexate—colon cancer	7.24e-05	0.00043	CcSEcCtD
Naproxen—Asthenia—Methotrexate—colon cancer	7.05e-05	0.000418	CcSEcCtD
Naproxen—Pruritus—Methotrexate—colon cancer	6.95e-05	0.000413	CcSEcCtD
Naproxen—Diarrhoea—Methotrexate—colon cancer	6.72e-05	0.000399	CcSEcCtD
Naproxen—Dizziness—Methotrexate—colon cancer	6.49e-05	0.000386	CcSEcCtD
Naproxen—Vomiting—Methotrexate—colon cancer	6.24e-05	0.000371	CcSEcCtD
Naproxen—Rash—Methotrexate—colon cancer	6.19e-05	0.000368	CcSEcCtD
Naproxen—Dermatitis—Methotrexate—colon cancer	6.19e-05	0.000367	CcSEcCtD
Naproxen—Headache—Methotrexate—colon cancer	6.15e-05	0.000365	CcSEcCtD
Naproxen—Nausea—Methotrexate—colon cancer	5.83e-05	0.000346	CcSEcCtD
Naproxen—SLCO1A2—Metabolism—ODC1—colon cancer	3.61e-05	0.00294	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—CHST5—colon cancer	3.61e-05	0.00294	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CA7—colon cancer	3.6e-05	0.00293	CbGpPWpGaD
Naproxen—PTGS2—Aryl Hydrocarbon Receptor—KRAS—colon cancer	3.55e-05	0.00289	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—ODC1—colon cancer	3.37e-05	0.00274	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—CHST5—colon cancer	3.37e-05	0.00274	CbGpPWpGaD
Naproxen—CYP2C9—Arachidonic acid metabolism—PTGS2—colon cancer	3.28e-05	0.00267	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—colon cancer	3.1e-05	0.00252	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	3.05e-05	0.00248	CbGpPWpGaD
Naproxen—PTGS2—Aryl Hydrocarbon Receptor—HRAS—colon cancer	3.02e-05	0.00245	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—colon cancer	3e-05	0.00244	CbGpPWpGaD
Naproxen—PTGS2—C-MYB transcription factor network—CCND1—colon cancer	2.96e-05	0.00241	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	2.93e-05	0.00238	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CA7—colon cancer	2.93e-05	0.00238	CbGpPWpGaD
Naproxen—ALB—Metabolism—CA7—colon cancer	2.91e-05	0.00237	CbGpPWpGaD
Naproxen—UGT2B7—NRF2 pathway—TGFB1—colon cancer	2.89e-05	0.00235	CbGpPWpGaD
Naproxen—PTGS2—C-MYB transcription factor network—CDKN1A—colon cancer	2.86e-05	0.00233	CbGpPWpGaD
Naproxen—CYP1A2—Arachidonic acid metabolism—PTGS2—colon cancer	2.81e-05	0.00228	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—ODC1—colon cancer	2.75e-05	0.00223	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—CHST5—colon cancer	2.75e-05	0.00223	CbGpPWpGaD
Naproxen—PTGS2—C-MYB transcription factor network—EP300—colon cancer	2.72e-05	0.00221	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—colon cancer	2.62e-05	0.00213	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—PPARG—colon cancer	2.61e-05	0.00212	CbGpPWpGaD
Naproxen—PTGS2—Disease—LGR5—colon cancer	2.61e-05	0.00212	CbGpPWpGaD
Naproxen—PTGS2—Disease—CHST5—colon cancer	2.61e-05	0.00212	CbGpPWpGaD
Naproxen—ALB—Selenium Micronutrient Network—PTGS2—colon cancer	2.55e-05	0.00207	CbGpPWpGaD
Naproxen—PTGS2—C-MYB transcription factor network—NRAS—colon cancer	2.55e-05	0.00207	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—EP300—colon cancer	2.5e-05	0.00203	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—colon cancer	2.5e-05	0.00203	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—SRC—colon cancer	2.43e-05	0.00197	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—colon cancer	2.43e-05	0.00197	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CA7—colon cancer	2.39e-05	0.00194	CbGpPWpGaD
Naproxen—PTGS2—C-MYB transcription factor network—MYC—colon cancer	2.37e-05	0.00193	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—colon cancer	2.36e-05	0.00192	CbGpPWpGaD
Naproxen—UGT1A1—NRF2 pathway—TGFB1—colon cancer	2.35e-05	0.00191	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—colon cancer	2.33e-05	0.0019	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—CASP3—colon cancer	2.32e-05	0.00188	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—CCND1—colon cancer	2.25e-05	0.00183	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—APC—colon cancer	2.24e-05	0.00182	CbGpPWpGaD
Naproxen—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—colon cancer	2.23e-05	0.00182	CbGpPWpGaD
Naproxen—PTGS2—C-MYB transcription factor network—KRAS—colon cancer	2.19e-05	0.00178	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CHST5—colon cancer	2.18e-05	0.00177	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—ODC1—colon cancer	2.18e-05	0.00177	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—MYC—colon cancer	2.17e-05	0.00177	CbGpPWpGaD
Naproxen—ALB—Platelet degranulation—VEGFA—colon cancer	2.17e-05	0.00176	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—colon cancer	2.17e-05	0.00176	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—colon cancer	2.13e-05	0.00173	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—colon cancer	2.13e-05	0.00173	CbGpPWpGaD
Naproxen—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—colon cancer	2.07e-05	0.00168	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	2.05e-05	0.00167	CbGpPWpGaD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—ABCB1—colon cancer	2.04e-05	0.00166	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CA7—colon cancer	2.04e-05	0.00166	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—colon cancer	2.01e-05	0.00163	CbGpPWpGaD
Naproxen—ALB—Platelet degranulation—TGFB1—colon cancer	1.99e-05	0.00162	CbGpPWpGaD
Naproxen—SLC22A6—Transmembrane transport of small molecules—ABCB1—colon cancer	1.92e-05	0.00156	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—TP53—colon cancer	1.91e-05	0.00155	CbGpPWpGaD
Naproxen—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—colon cancer	1.9e-05	0.00154	CbGpPWpGaD
Naproxen—PTGS2—Disease—AXIN2—colon cancer	1.87e-05	0.00152	CbGpPWpGaD
Naproxen—PTGS2—C-MYB transcription factor network—HRAS—colon cancer	1.86e-05	0.00152	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—MYC—colon cancer	1.81e-05	0.00147	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—TGFB1—colon cancer	1.8e-05	0.00147	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ODC1—colon cancer	1.78e-05	0.00144	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CHST5—colon cancer	1.78e-05	0.00144	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—EGFR—colon cancer	1.77e-05	0.00144	CbGpPWpGaD
Naproxen—ALB—Metabolism—ODC1—colon cancer	1.77e-05	0.00144	CbGpPWpGaD
Naproxen—ALB—Metabolism—CHST5—colon cancer	1.77e-05	0.00144	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—colon cancer	1.71e-05	0.00139	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.71e-05	0.00139	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—ABCB1—colon cancer	1.67e-05	0.00136	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—TYMS—colon cancer	1.64e-05	0.00133	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	1.58e-05	0.00128	CbGpPWpGaD
Naproxen—AKR1C3—Disease—FGFR3—colon cancer	1.56e-05	0.00127	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	1.53e-05	0.00125	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	1.52e-05	0.00123	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.49e-05	0.00121	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—TP53—colon cancer	1.49e-05	0.00121	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	1.48e-05	0.00121	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ODC1—colon cancer	1.45e-05	0.00117	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CHST5—colon cancer	1.45e-05	0.00117	CbGpPWpGaD
Naproxen—AKR1C3—Disease—APC—colon cancer	1.44e-05	0.00117	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	1.41e-05	0.00115	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	1.37e-05	0.00112	CbGpPWpGaD
Naproxen—AKR1C3—Disease—BRAF—colon cancer	1.35e-05	0.0011	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	1.34e-05	0.00109	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.26e-05	0.00103	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CHST5—colon cancer	1.24e-05	0.001	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ODC1—colon cancer	1.24e-05	0.001	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	1.23e-05	0.001	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	1.23e-05	0.000998	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	1.2e-05	0.000978	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.17e-05	0.000954	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PPARG—colon cancer	1.16e-05	0.000944	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	1.14e-05	0.000924	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.14e-05	0.000923	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—ABCB1—colon cancer	1.1e-05	0.000892	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—FGFR3—colon cancer	1.1e-05	0.000891	CbGpPWpGaD
Naproxen—AKR1C3—Disease—PTGS2—colon cancer	1.09e-05	0.000887	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—TYMS—colon cancer	1.08e-05	0.000876	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	1.04e-05	0.000849	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	1.01e-05	0.000821	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—APC—colon cancer	1.01e-05	0.000818	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—ABCB1—colon cancer	9.96e-06	0.00081	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—SRC—colon cancer	9.88e-06	0.000803	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—EP300—colon cancer	9.76e-06	0.000793	CbGpPWpGaD
Naproxen—AKR1C3—Disease—CTNNB1—colon cancer	9.76e-06	0.000793	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—VEGFA—colon cancer	9.63e-06	0.000782	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—ABCB1—colon cancer	9.55e-06	0.000776	CbGpPWpGaD
Naproxen—AKR1C3—Disease—CDKN1A—colon cancer	9.54e-06	0.000775	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—BRAF—colon cancer	9.46e-06	0.000769	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—TYMS—colon cancer	9.38e-06	0.000762	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PTGS2—colon cancer	9.14e-06	0.000743	CbGpPWpGaD
Naproxen—AKR1C3—Disease—EP300—colon cancer	9.07e-06	0.000737	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	9.01e-06	0.000732	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	8.93e-06	0.000726	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—ABCB1—colon cancer	8.91e-06	0.000724	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—TGFB1—colon cancer	8.84e-06	0.000718	CbGpPWpGaD
Naproxen—AKR1C3—Disease—SRC—colon cancer	8.82e-06	0.000717	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—TYMS—colon cancer	8.75e-06	0.000711	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	8.53e-06	0.000693	CbGpPWpGaD
Naproxen—AKR1C3—Disease—NRAS—colon cancer	8.49e-06	0.00069	CbGpPWpGaD
Naproxen—AKR1C3—Disease—MYC—colon cancer	7.91e-06	0.000643	CbGpPWpGaD
Naproxen—AKR1C3—Disease—TGFB1—colon cancer	7.89e-06	0.000641	CbGpPWpGaD
Naproxen—AKR1C3—Disease—EGFR—colon cancer	7.73e-06	0.000629	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PPARG—colon cancer	7.63e-06	0.00062	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—EP300—colon cancer	7.6e-06	0.000618	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—PIK3CA—colon cancer	7.52e-06	0.000611	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—EP300—colon cancer	7.43e-06	0.000604	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—colon cancer	7.33e-06	0.000596	CbGpPWpGaD
Naproxen—AKR1C3—Disease—KRAS—colon cancer	7.31e-06	0.000594	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PPARG—colon cancer	7.29e-06	0.000593	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—ABCB1—colon cancer	7.27e-06	0.000591	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	7.22e-06	0.000587	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—TYMS—colon cancer	7.14e-06	0.00058	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CASP3—colon cancer	7.09e-06	0.000576	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CCND1—colon cancer	6.9e-06	0.000561	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CTNNB1—colon cancer	6.84e-06	0.000556	CbGpPWpGaD
Naproxen—AKR1C3—Disease—PIK3CA—colon cancer	6.71e-06	0.000545	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CDKN1A—colon cancer	6.68e-06	0.000543	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PPARG—colon cancer	6.65e-06	0.00054	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—EP300—colon cancer	6.35e-06	0.000516	CbGpPWpGaD
Naproxen—AKR1C3—Disease—HRAS—colon cancer	6.21e-06	0.000505	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PPARG—colon cancer	6.2e-06	0.000504	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—SRC—colon cancer	6.18e-06	0.000502	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—AKT1—colon cancer	6.14e-06	0.000499	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—VEGFA—colon cancer	6.02e-06	0.000489	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PTGS2—colon cancer	6e-06	0.000488	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—colon cancer	5.97e-06	0.000485	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—NRAS—colon cancer	5.94e-06	0.000483	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—EP300—colon cancer	5.9e-06	0.000479	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—ABCB1—colon cancer	5.77e-06	0.000469	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	5.77e-06	0.000469	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	5.73e-06	0.000466	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—TYMS—colon cancer	5.66e-06	0.00046	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PIK3CA—colon cancer	5.62e-06	0.000457	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MYC—colon cancer	5.54e-06	0.00045	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TGFB1—colon cancer	5.52e-06	0.000449	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	5.49e-06	0.000447	CbGpPWpGaD
Naproxen—AKR1C3—Disease—AKT1—colon cancer	5.48e-06	0.000446	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—EGFR—colon cancer	5.42e-06	0.00044	CbGpPWpGaD
Naproxen—PTGS2—Disease—FGFR3—colon cancer	5.41e-06	0.00044	CbGpPWpGaD
Naproxen—ALB—Hemostasis—EP300—colon cancer	5.24e-06	0.000426	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PTGS2—colon cancer	5.23e-06	0.000425	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—KRAS—colon cancer	5.12e-06	0.000416	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	5.1e-06	0.000414	CbGpPWpGaD
Naproxen—ALB—Hemostasis—SRC—colon cancer	5.09e-06	0.000414	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PPARG—colon cancer	5.06e-06	0.000411	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—EP300—colon cancer	4.99e-06	0.000406	CbGpPWpGaD
Naproxen—PTGS2—Disease—APC—colon cancer	4.96e-06	0.000404	CbGpPWpGaD
Naproxen—ALB—Hemostasis—VEGFA—colon cancer	4.96e-06	0.000403	CbGpPWpGaD
Naproxen—ALB—Hemostasis—NRAS—colon cancer	4.9e-06	0.000398	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PTGS2—colon cancer	4.88e-06	0.000396	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—EP300—colon cancer	4.8e-06	0.00039	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—EP300—colon cancer	4.77e-06	0.000388	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PIK3CA—colon cancer	4.7e-06	0.000382	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	4.69e-06	0.000382	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ABCB1—colon cancer	4.69e-06	0.000381	CbGpPWpGaD
Naproxen—PTGS2—Disease—BRAF—colon cancer	4.67e-06	0.000379	CbGpPWpGaD
Naproxen—ALB—Metabolism—ABCB1—colon cancer	4.67e-06	0.000379	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—TYMS—colon cancer	4.61e-06	0.000375	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—AKT1—colon cancer	4.59e-06	0.000373	CbGpPWpGaD
Naproxen—ALB—Metabolism—TYMS—colon cancer	4.58e-06	0.000373	CbGpPWpGaD
Naproxen—ALB—Hemostasis—TGFB1—colon cancer	4.55e-06	0.00037	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TP53—colon cancer	4.55e-06	0.00037	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	4.36e-06	0.000354	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—HRAS—colon cancer	4.35e-06	0.000353	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—EP300—colon cancer	4.35e-06	0.000353	CbGpPWpGaD
Naproxen—ALB—Hemostasis—KRAS—colon cancer	4.22e-06	0.000343	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—EP300—colon cancer	4.06e-06	0.00033	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PPARG—colon cancer	4.01e-06	0.000326	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	4.01e-06	0.000326	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PTGS2—colon cancer	3.98e-06	0.000323	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—EP300—colon cancer	3.9e-06	0.000317	CbGpPWpGaD
Naproxen—ALB—Hemostasis—PIK3CA—colon cancer	3.88e-06	0.000315	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—AKT1—colon cancer	3.84e-06	0.000312	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ABCB1—colon cancer	3.82e-06	0.00031	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—TYMS—colon cancer	3.75e-06	0.000305	CbGpPWpGaD
Naproxen—ALB—Hemostasis—TP53—colon cancer	3.75e-06	0.000305	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PIK3CA—colon cancer	3.69e-06	0.0003	CbGpPWpGaD
Naproxen—ALB—Hemostasis—HRAS—colon cancer	3.59e-06	0.000291	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	3.55e-06	0.000288	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	3.53e-06	0.000287	CbGpPWpGaD
Naproxen—PTGS2—Disease—CTNNB1—colon cancer	3.37e-06	0.000274	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—EP300—colon cancer	3.34e-06	0.000271	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—EP300—colon cancer	3.31e-06	0.000269	CbGpPWpGaD
Naproxen—PTGS2—Disease—CDKN1A—colon cancer	3.29e-06	0.000268	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PPARG—colon cancer	3.27e-06	0.000265	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ABCB1—colon cancer	3.26e-06	0.000265	CbGpPWpGaD
Naproxen—ALB—Metabolism—PPARG—colon cancer	3.25e-06	0.000264	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PIK3CA—colon cancer	3.22e-06	0.000261	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—TYMS—colon cancer	3.21e-06	0.000261	CbGpPWpGaD
Naproxen—ALB—Hemostasis—AKT1—colon cancer	3.17e-06	0.000257	CbGpPWpGaD
Naproxen—PTGS2—Disease—EP300—colon cancer	3.14e-06	0.000255	CbGpPWpGaD
Naproxen—PTGS2—Disease—SRC—colon cancer	3.05e-06	0.000248	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—AKT1—colon cancer	3.02e-06	0.000245	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PIK3CA—colon cancer	3e-06	0.000244	CbGpPWpGaD
Naproxen—PTGS2—Disease—NRAS—colon cancer	2.93e-06	0.000238	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	2.89e-06	0.000235	CbGpPWpGaD
Naproxen—PTGS2—Disease—MYC—colon cancer	2.73e-06	0.000222	CbGpPWpGaD
Naproxen—PTGS2—Disease—TGFB1—colon cancer	2.73e-06	0.000222	CbGpPWpGaD
Naproxen—PTGS2—Disease—EGFR—colon cancer	2.67e-06	0.000217	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PPARG—colon cancer	2.66e-06	0.000216	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—AKT1—colon cancer	2.63e-06	0.000214	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—EP300—colon cancer	2.63e-06	0.000213	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PTGS2—colon cancer	2.57e-06	0.000209	CbGpPWpGaD
Naproxen—ALB—Metabolism—PTGS2—colon cancer	2.55e-06	0.000208	CbGpPWpGaD
Naproxen—PTGS2—Disease—KRAS—colon cancer	2.52e-06	0.000205	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	2.47e-06	0.000201	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—AKT1—colon cancer	2.45e-06	0.000199	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PIK3CA—colon cancer	2.45e-06	0.000199	CbGpPWpGaD
Naproxen—PTGS2—Disease—PIK3CA—colon cancer	2.32e-06	0.000188	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PPARG—colon cancer	2.27e-06	0.000185	CbGpPWpGaD
Naproxen—PTGS2—Disease—HRAS—colon cancer	2.15e-06	0.000174	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—EP300—colon cancer	2.14e-06	0.000174	CbGpPWpGaD
Naproxen—ALB—Metabolism—EP300—colon cancer	2.12e-06	0.000173	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PTGS2—colon cancer	2.09e-06	0.00017	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—AKT1—colon cancer	2e-06	0.000162	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PIK3CA—colon cancer	1.94e-06	0.000158	CbGpPWpGaD
Naproxen—PTGS2—Disease—AKT1—colon cancer	1.89e-06	0.000154	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PTGS2—colon cancer	1.79e-06	0.000145	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—EP300—colon cancer	1.74e-06	0.000141	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—AKT1—colon cancer	1.59e-06	0.000129	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PIK3CA—colon cancer	1.58e-06	0.000128	CbGpPWpGaD
Naproxen—ALB—Metabolism—PIK3CA—colon cancer	1.57e-06	0.000128	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—EP300—colon cancer	1.49e-06	0.000121	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—AKT1—colon cancer	1.29e-06	0.000105	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PIK3CA—colon cancer	1.29e-06	0.000105	CbGpPWpGaD
Naproxen—ALB—Metabolism—AKT1—colon cancer	1.28e-06	0.000104	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PIK3CA—colon cancer	1.1e-06	8.93e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—AKT1—colon cancer	1.05e-06	8.54e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—AKT1—colon cancer	8.98e-07	7.3e-05	CbGpPWpGaD
